Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.

Lewden C, Gabillard D, Minga A, Ekouévi DK, Avit D, Konate I, Amani-Bossé C, Messou E, Coffie P, Ouedraogo A, Laurent C, Anglaret X; ANRS 12222 MorbidityMortality Study Group..

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):213-9. doi: 10.1097/QAI.0b013e31823b837e.

2.

Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group..

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821.

3.

AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.

Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; ANRS 12222 Morbidity/Mortality Study Group..

Clin Infect Dis. 2012 Mar 1;54(5):714-23. doi: 10.1093/cid/cir898. Epub 2012 Feb 4.

4.

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

TEMPRANO ANRS 12136 Study Group., Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibé B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouamé E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundzé S, Hawerlander D, Ani A, Dembélé F, Koné F, Guéhi C, Kanga C, Koule S, Séri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semdé C, Kouame A, Massumbuko JM, Chêne G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholié SP, Anglaret X.

N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20.

5.

Temporal trends in mortality and loss to follow-up among children enrolled in Côte d'Ivoire's national antiretroviral therapy program.

Auld AF, Tuho MZ, Ekra KA, Shiraishi RW, Mohamed F, Kouakou JS, Ettiègne-Traoré V, Sabatier J, Essombo J, Rivadeneira ED, Adjorlolo-Johnson G, Marlink R, Ellerbrock TV.

Pediatr Infect Dis J. 2014 Nov;33(11):1134-40. doi: 10.1097/INF.0000000000000457.

PMID:
25093975
6.

Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs.

Verguet S, Lim SS, Murray CJ, Gakidou E, Salomon JA.

J Infect Dis. 2013 Jan 1;207(1):72-9. doi: 10.1093/infdis/jis635. Epub 2012 Oct 24.

PMID:
23100567
7.

Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.

Alvarez-Uria G, Naik PK, Pakam R, Midde M.

Glob Health Action. 2013 Sep 12;6:21682. doi: 10.3402/gha.v6i0.21682.

8.

Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa.

Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, Lawn SD, Wood R, Bekker LG.

BMC Infect Dis. 2012 Jan 25;12:21. doi: 10.1186/1471-2334-12-21.

9.

Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.

De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, Prosperi MC, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.

PMID:
22327246
10.

Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholié S, Freedberg KA.

Antivir Ther. 2013;18(1):45-55. doi: 10.3851/IMP2231. Epub 2012 Jul 18.

11.

Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program.

Auld AF, Ekra KA, Shiraishi RW, Tuho MZ, Kouakou JS, Mohamed F, Ettiègne-Traoré V, Sabatier J, Essombo J, Adjorlolo-Johnson G, Marlink R, Ellerbrock TV.

PLoS One. 2014 May 27;9(5):e98183. doi: 10.1371/journal.pone.0098183. eCollection 2014.

12.

Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling Analysis.

Schomaker M, Davies MA, Malateste K, Renner L, Sawry S, N'Gbeche S, Technau KG, Eboua F, Tanser F, Sygnaté-Sy H, Phiri S, Amorissani-Folquet M, Cox V, Koueta F, Chimbete C, Lawson-Evi A, Giddy J, Amani-Bosse C, Wood R, Egger M, Leroy V; IeDEA West Africa and IeDEA Southern Africa collaboration..

Epidemiology. 2016 Mar;27(2):237-46. doi: 10.1097/EDE.0000000000000412.

13.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators..

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
14.

Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008.

Abo Y, Minga A, Menan H, Danel C, Ouassa T, Dohoun L, Bomisso G, Tanoh A, Messou E, Eholié S, Lewden C, Anglaret X.

BMC Infect Dis. 2013 Dec 27;13:607. doi: 10.1186/1471-2334-13-607.

15.

Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.

Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group..

Antivir Ther. 2003 Oct;8(5):385-93.

PMID:
14640385
16.

Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.

Farahani M, Vable A, Lebelonyane R, Seipone K, Anderson M, Avalos A, Chadborn T, Tilahun H, Roumis D, Moeti T, Musuka G, Busang L, Gaolathe T, Malefho KC, Marlink R.

Lancet Glob Health. 2014 Jan;2(1):e44-50. doi: 10.1016/S2214-109X(13)70149-9. Epub 2013 Dec 11.

17.

First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration.

Drylewicz J, Eholie S, Maiga M, Zannou DM, Sow PS, Ekouevi DK, Peterson K, Bissagnene E, Dabis F, Thiébaut R; International epidemiologic Databases to Evaluate AIDS (IeDEA) West Africa Collaboration..

AIDS. 2010 Apr 24;24(7):1043-50.

18.

Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.

Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1338-47. doi: 10.1089/aid.2006.0308.

19.

Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults.

Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML.

PLoS One. 2011;6(7):e21795. doi: 10.1371/journal.pone.0021795. Epub 2011 Jul 1.

20.

Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.

Carriquiry G, Fink V, Koethe JR, Giganti MJ, Jayathilake K, Blevins M, Cahn P, Grinsztejn B, Wolff M, Pape JW, Padgett D, Madero JS, Gotuzzo E, McGowan CC, Shepherd BE.

J Int AIDS Soc. 2015 Jul 10;18:20016. doi: 10.7448/IAS.18.1.20016. eCollection 2015.

Supplemental Content

Support Center